Analysis of the Immunotherapy Drugs Market: Assessment of Market Size, Trends, Statistics, and Competitors
Global Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Checkpoint Inhibitors, Vaccines, Interferons & Interleukins, and Others), by Indication (Cancer, Autoimmune diseases & Inflammatory Diseases, Infectious Diseases, and Others), and by Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) – Market Size, Share, COVID-19 Impact, Regional Analysis & Forecast Till 2030
Category - Healthcare
Report Code - OMR-H-140
Format: PDF, PPT, and Excel
Immunotherapy Drugs Market Overview
Immunotherapy is any treatment that uses the patient's immune system to combat cancer. The immune system can be stimulated or retrained with immunotherapy, allowing it to locate better and destroy cancer cells. Immunotherapy's role in combating various forms of cancer has grown significantly during the past few decades. Rapid progress is being made in developing immunotherapy and other methods of manipulating the immune system. Many immunotherapy treatments for cancer treatment have been authorized, and hundreds more are in clinical development (research studies that use volunteers to test new medicines). It may improve the effectiveness of other cancer therapies. Including immunotherapy in your treatment plan may improve the efficacy of other medicines you're receiving, like chemotherapy. When compared to other therapies, it has fewer negative effects. This is because it selectively attacks the immune system rather than the body as a whole. Certain forms of immunotherapy stimulate the immune system, making you feel sick with a fever, chills, and exhaustion, much like when you have the flu. Some may produce uncomfortable side effects, including fluid retention and weight gain, irregular heartbeat, shortness of breath, and diarrhea. Most people report a decrease in these during the initial course of medication. The rapid spread of the COVID-19 pandemic positively affected the immunotherapy pharmaceuticals industry, which led to a greater need for these medications due to the virus's relative safety and effectiveness.
Immunotherapy Drugs Market Growth Factors
Growing Advances in the Field of Immunotherapy to Boost The Market Growth
Treatments based on immunotherapy have sparked new interest in tumor immunology and ushered in a new era for cancer research. Although many forms of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have achieved long-lasting clinical responses, these treatments' efficacies vary and are effective for only a portion of cancer patients. Clinical outcomes for cancer patients are affected by immune infiltrates in the tumor microenvironment (TME), which have been proven to play an important role in tumor growth. An in-depth analysis of immune cells within tumors might reveal previously unknown mechanisms of cancer immune evasion, opening the door to new treatment approaches. Companies in the market are also talking about initiatives to develop novel immunotherapies. For instance, in February 2022, with the help of Institut Curie, Biomunex Pharmaceuticals began working on an immunotherapy medication candidate for treating hematological malignancies with their BiXAR technology.
Rising Prevalence Cancer to Augment Market Growth
There has been a steady increase in the incidence of several chronic illnesses worldwide, many requiring immune-based therapy. Cancer, renal failure, autoimmune and inflammatory illnesses, and cardiovascular disorders are all examples of major chronic diseases. The World Health Organization estimates that by 2020, cancer will be responsible for over 10 million deaths globally. Cancers of the breast, lungs, intestines, cervix, and prostate are the most prevalent. Moreover, projected cancer incidence and mortality rates in 2022 are provided by the American Cancer Society, Inc., i.e., in 2022, an estimated 1.9 million new cancer cases will be diagnosed and 609,360 cancer deaths in the United States. The rising cancer rate among populations throughout the world is one factor that is likely to propel the industry forward. The worldwide market for immunotherapy drugs is expected to rise due to increasing research and development efforts into creating innovative immunotherapies for various chronic illnesses. Several different immunotherapies are now in use to combat cancer. Cancer vaccines, immune system modulators, and T-cell cell transfers are all examples of immunotherapies. These treatments are utilized for various cancers and their later stages.
Immunotherapy Drugs Industry Segmentation
Type
• Monoclonal Antibodies
• Checkpoint Inhibitors
• Vaccines
• Interferons & Interleukins
• Others
Indication
• Cancer
• Autoimmune Diseases & Inflammatory Diseases
• Infectious Diseases
• Others
Immunotherapy Drugs Market Regional Segmentation
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe (RoE)
Asia Pacific (APAC)
o Japan
o China
o India
o South Korea
o Rest of APAC
Latin America
o Argentina
o Brazil
o Rest of Latin America
Middle East & Africa
o South Africa
o UAE
o Saudi Arabia
o Rest of MEA
Type Insights
Monoclonal Antibodies are Dominant as their R&D Studies are Heavily Funded
Based on type, the market can be differentiated between monoclonal antibodies, checkpoint inhibitors, vaccines, interferons & interleukins, and others.
The monoclonal antibodies are anticipated to hold the largest share of the market. Increased research and development of therapeutic monoclonal antibodies and supporting government initiatives are credited with driving the industry forward. Cancer treatment using monoclonal antibody-mediated immunotherapy may be possible without harming healthy cells. It helps the immune system fight cancer and has fewer negative side effects than many other treatments. To aid the immune system in locating and destroying cancer cells, scientists have discovered that labeling the cells with specific monoclonal antibodies might greatly improve detection.
The vaccines segment is expected to expand at a particularly rapid clip throughout the projected period. The increased burden of numerous illnesses and diseases is driving investments in the development of vaccines. In addition, strategic partnerships between major businesses and an uptick in clinical vaccination studies are credited with driving this segment's growth.
Regional Insights
Asia Pacific to Lead Global Sales Owing to Growing Cancer Prevalence
Based on region, the market can be split between North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
North America is predicted to hold a large share of the global market. This is because of the region's rising elder population, rising cancer incidence rates, and increased preferences for and use of immunotherapy. In the United States in 2020, according to projections from the Globocan, over 2,556,862 new cancer cases were detected. Cancers of the breast, lungs, prostate, intestines, urinary tract, and skin are the most prevalent types in the United States. Almost half of Americans deal with the effects of at least one chronic condition. There has been a corresponding rise in the cost of medical treatment. In addition, the presence of a highly developed healthcare infrastructure and several leading biopharmaceutical businesses has greatly aided the expansion of the market.
One of the key factors driving the market growth in the Asia Pacific includes the rising number of clinical studies, including immunotherapy, in the region. Market expansion is forecast to be led by a combination of factors, including a favorable regulatory framework and rising consumer demand. Regulatory agencies have begun developing frameworks and approaches to regulating this new wave of innovative research and development. As a result, cutting-edge immunotherapies are anticipated to be in high demand there. In addition, rising cancer rates are contributing to the growing market in this region. The GLOBOCAN study estimates that in 2020 there will be 27,10,728 persons in Japan with cancer, with 10,28,658 newly diagnosed.
The growth of the immunotherapy drugs market in Europe is driven by the rising incidence of cancer, contagious diseases, and autoimmune disorders, as well as the increasing preference for immunotherapy drugs over conventional treatment methods. The rising incidence of cancer is one of the key factors driving the immunotherapy drugs market in Europe. Cancer is the second leading cause of mortality in Europe, accounting for 22 percent of all deaths, according to the World Health Organization (WHO). Lung cancer, breast cancer, colorectal cancer, and prostate cancer are the most prevalent types of cancer in Europe.
Immunotherapy Drugs Industry Analysis
Competitors in the Immunotherapy Drugs market sometimes try to gain a larger slice of the pie by various means, such as by expanding into new geographical markets or introducing cutting-edge goods. They also work to differentiate themselves in the marketplace by improving their existing product lines and promoting their products.
Players in the sector resort to various strategies to maintain their position, including mergers and acquisitions, contracts, and partnerships with IT companies. Massive expenditures have been made to develop Immunotherapy Pharmaceuticals, creating a harsh environment for those who compete in the global immunotherapy drugs market.
Immunotherapy Drugs Market Recent Developments
• In October 2022, Hookipa Pharma and Roche have formed a strategic cooperation and license agreement to develop HB-700 and other arenaviral immunotherapy that has not been revealed. Under the terms of the agreement, Hookipa will conduct research and Phase Ib clinical development for HB-700 to treat KRAS-mutated tumors.
• In January 2022, Pfizer Inc.'s CIBINQO (abrocitinib) was approved by the Food and Drug Administration (FDA) as an oral therapy, Janus kinase 1 inhibitor, to treat people with refractory moderate-to-severe atopic dermatitis.
Global Immunotherapy Drugs Market Prominent Players
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• AbbVie Inc. (U.S.)
• AstraZeneca (UK)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Amgen Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Bayer AG (Germany)
• GSK plc. (U.S.)
• Sanofi (France)
Frequently Asked Questions (FAQs)
At what rate will the Immunotherapy Drugs Market Expand?
The global Immunotherapy Drugs Market will expand at a CAGR of 10.9% over the forecast period, according to research from Objective Market Research.
What are the factors driving the global Immunotherapy Drugs market?
The global Immunotherapy Drugs market is expected to grow during the forecast period owing to the rising prevalence of cancer and autoimmune diseases and the growing demand for biosimilars.
Which segment accounted for the largest Immunotherapy Drugs market share by indication?
The cancer segment is expected to dominate the largest market share during the forecast period as the prevalence of cancer is growing every year.
What region holds the major share in the global market scape?
North America will hold the largest share of the market owing to the rising investments in the healthcare sector and the presence of major immunotherapy drug manufacturers.
Which are the dominating players in the market during the forecast period?
Some of the prominent players in the global immunotherapy drugs market are Novartis AG, Pfizer Inc., AbbVie Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Amgen Inc, Johnson & Johnson Services, Inc., Bayer AG, GSK plc., and Sanofi, among others.
*Our reports are available on a region/wise and chapter/wise basis as well. For any additional personalization contact our sales representative directly at sales@objectivemarketresearch.com
Table of Content
1. Introduction
1.1 Market Definition
1.2 Objective of the Study
1.3 Market Scope
1.4 Years Considered in the Study
1.4.1 Historic Year: 2019-2021
1.4.2 Base Year: 2022
1.4.3 Forecast Period: 2023-2030
1.5 Currency Used in the Study
1.6 Boundaries for the Study
1.7 Collaborators/Stakeholders/Benefactors
2. Research Methodology
2.1 Research Outline
2.2 Data Collection Methods
2.3 Data Sources
2.3.1 Secondary Sources
2.3.1.1 Paid Sources
2.3.1.2 Unpaid Sources
2.3.2 Primary Sources
2.4 Market Estimation Methodology
2.4.1 Top-Down Approach
2.4.2 Bottom-Up Approach
2.5 Data Triangulation
2.6 Assumptions of the Study
2.7 Limitations of the Study
3. Executive Summary
3.1 Market Outlook
3.2 Analysts Perspective
4. Market Overview
4.1 Market Dynamics
4.1.1 Drivers
4.1.1.1. Rising prevalence of cancer and autoimmune diseases
4.1.1.2. Growing demand for biosimilars
4.1.2. Restrain
4.1.2.1. Side effects of the drugs
4.1.3. Opportunities
4.1.3.1. Growing R&D activities
4.1.4. Impact of Market Dynamics
4.2. Impact of COVID-19 pandemic
4.3. Value Chain Analysis
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitution
4.4.4. Threat of New Entrants
4.4.5. Competitive Rivalry
5. Global Immunotherapy Drugs Market Analysis & Forecast, by Type from 2019-2030 (in USD million)
5.1. Monoclonal Antibodies
5.2. Checkpoint Inhibitors
5.3. Vaccines
5.4. Interferons & Interleukins
5.5. Others
6. Global Immunotherapy Drugs Market Analysis & Forecast, by Indication from 2019-2030 (in USD million)
6.1. Cancer
6.2. Autoimmune diseases & Inflammatory Diseases
6.3. Infectious diseases
6.4. Others
7. Global Immunotherapy Drugs Market Analysis & Forecast, by Region from 2019-2030 (in USD million)
7.1. North America
7.1.1. North America Immunotherapy Drugs Market Analysis & Forecast, By Country
7.1.1.1. U.S.
7.1.1.2. Canada
7.1.1.3. Mexico
7.1.2. North America Immunotherapy Drugs Market Analysis & Forecast, By Type
7.1.3. North America Immunotherapy Drugs Market Analysis & Forecast, By Indication
7.2. Europe
7.2.1. Europe Immunotherapy Drugs Market Analysis & Forecast, By Country
7.2.1.1. Germany
7.2.1.2. UK
7.2.1.3. France
7.2.1.4. Spain
7.2.1.5. Italy
7.2.1.6. Rest of Europe (RoE)
7.2.2. Europe Immunotherapy Drugs Market Analysis & Forecast, By Type
7.2.3. Europe Immunotherapy Drugs Market Analysis & Forecast, By Indication
7.3. Asia-Pacific (APAC)
7.3.1. Asia-Pacific Immunotherapy Drugs Market Analysis & Forecast, By Country
7.3.1.1. Japan
7.3.1.2. China
7.3.1.3. India
7.3.1.4. South Korea
7.3.1.5. Rest of the APAC
7.3.2. Asia-Pacific Immunotherapy Drugs Market Analysis & Forecast, By Type
7.3.3. Asia-Pacific Immunotherapy Drugs Market Analysis & Forecast, By Indication
7.4. Latin America
7.4.1. Latin America Digital Therapeutics Market Analysis & Forecast, By Country/Region
7.4.1.1. Argentina
7.4.1.2. Brazil
7.4.1.3. Rest of Latin America
7.4.2. Latin America Digital Therapeutics Market Analysis & Forecast, By Type
7.4.3. Latin America Digital Therapeutics Market Analysis & Forecast, By Indication
7.5. Middle East & Africa
7.5.1. Middle East & Africa Digital Therapeutics Market Analysis & Forecast, By Country/Region
7.5.1.1. South Africa
7.5.1.2. UAE
7.5.1.3. Saudi Arabia
7.5.1.4. Rest of Middle East & Africa
7.5.2. Middle East & Africa Digital Therapeutics Market Analysis & Forecast, By Type
7.5.3. Middle East & Africa Digital Therapeutics Market Analysis & Forecast, By Indication
8. Competitive Landscape
8.1. Market Share Analysis (2022)
8.2. Market Positioning of Top Players (2022)
8.3. Key Developments & Growth Strategies (2020-2022)
8.3.1. Product Launches
8.3.2. Merges, Collaborations & Agreements
8.3.3. Expansion
8.4. SWOT Analysis
9. Company Profiles (Business Overview, Products Offered, Financial Details*, Recent Developments)
9.1. Novartis AG
9.1.1. Company Snapshot
9.1.2. Business Overview
9.1.3. Financial Data
9.1.4. Key Products Offered
9.1.5. Recent Developments
9.2. Pfizer Inc.
9.3. AbbVie Inc.
9.4. AstraZeneca
9.5. F. Hoffmann-La Roche Ltd
9.6. Amgen Inc.
9.7. Johnson & Johnson Services, Inc.
9.8. Bayer AG
9.9. GSK plc.
9.10. Sanofi
9.11. Others
10. Appendix
10.1. Currency Exchange Rate to USD
10.2. Abbreviations
* Financial details captured might be subjected to information available and not be given for privately-held companies or for companies that do not report it in the public domain